PGRN Polypeptide Detection and Treatment for Frontotemporal Dementia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for effectively detecting mutations linked to frontotemporal dementia and treating the associated neurodegenerative disorders, particularly in relation to progranulin (PGRN) nucleic acid mutations, which are crucial for diagnosing and managing the disease.
Innovation Solution
The use of a PGRN polypeptide comprising a specific amino acid sequence (SEQ ID NO:1) and its encoding nucleic acid for treating and diagnosing frontotemporal dementia, involving methods for detecting mutations and increasing PGRN levels in mammals using agents like NSAIDs and PPAR agonists.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current detection methods are used for PGRN mutations, then diagnostic capability is limited, but implementation complexity and cost remain manageable
Solution Approach 1:
The patent extracts and focuses specifically on the PGRN gene region for detection, using targeted approaches such as allele-specific oligonucleotide hybridization and sequence-specific PCR primers that isolate the mutation detection process from general genomic analysis, thereby improving detection accuracy while controlling complexity
Solution Approach 2:
The patent employs intermediary molecules such as allele-specific oligonucleotides and probes that mediate between the complex genomic DNA and the detection system, enabling precise mutation detection through hybridization-based methods that are simpler than direct sequencing while maintaining high accuracy
2Reliability
If PGRN levels are increased to treat FTD, then therapeutic effectiveness improves, but risk of adverse effects increases
Solution Approach 1:
The patent uses PPAR agonists and NSAIDs as preliminary therapeutic agents that safely increase PGRN levels before disease progression becomes severe, allowing for preventive treatment that reduces the need for more aggressive interventions with higher adverse effect profiles
Solution Approach 2:
The patent modifies the biochemical parameters of the disease environment by using PPAR agonists and NSAIDs to alter gene expression and protein levels, increasing PGRN through physiological regulatory pathways rather than direct protein administration, thereby reducing immunogenicity and adverse effects
Data Source
Figure 1a~1c
Figure 2a~2d
Figure 3A~3B
AI summary
This document relates to methods and materials for detecting mutations that can be linked to dementia. For example, methods and materials for detecting one or more mutations within PGRN nucleic acid are provided. This document also provides methods and materials for detecting the level of progranulin expression. In addition, this document relates to methods and materials for treating mammals having a neurodegenerative disorder (e.g., dementia). For example, methods and materials for increasing PGRN polypeptide levels in mammals are provided, as are methods and materials for identifying agents that can be used to increase PGRN polypeptide levels in mammals.